Insulin-like Growth Factor II Prevents MPP+ and Glucocorticoid Mitochondrial-Oxidative and Neuronal Damage in Dopaminergic Neurons.
Silvia ClarosPablo CabreraNadia ValverdeSilvana Y Romero-ZerboManuel Victor López-GonzálezKirill ShumilovAlicia RiveraJosé PaviaElisa Martín-MontañezMaría Inmaculada García-FernándezPublished in: Antioxidants (Basel, Switzerland) (2021)
Stress seems to contribute to Parkinson's disease (PD) neuropathology, probably by dysregulation of the hypothalamic-pituitary-adrenal axis. Key factors in this pathophysiology are oxidative stress and mitochondrial dysfunction and neuronal glucocorticoid-induced toxicity. The insulin-like growth factor II (IGF-II), a pleiotropic hormone, has shown antioxidant and neuroprotective effects in some neurodegenerative disorders. Our aim was to examine the protective effect of IGF-II on a dopaminergic cellular combined model of PD and mild to moderate stress measuring oxidative stress parameters, mitochondrial and neuronal markers, and signalling pathways. IGF-II counteracts the mitochondrial-oxidative damage produced by the toxic synergistic effect of corticosterone and 1-methyl-4-phenylpyridinium, protecting dopaminergic neurons from death and neurodegeneration. IGF-II promotes PKC activation and nuclear factor (erythroid-derived 2)-like 2 antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage and maintaining mitochondrial function. Thus, IGF-II is a potential therapeutic tool for treatment and prevention of disease progression in PD patients suffering mild to moderate emotional stress.
Keyphrases
- oxidative stress
- diabetic rats
- growth hormone
- ischemia reperfusion injury
- dna damage
- nuclear factor
- binding protein
- induced apoptosis
- end stage renal disease
- pi k akt
- immune response
- single cell
- chronic kidney disease
- stress induced
- mouse model
- cancer therapy
- blood brain barrier
- heat shock
- inflammatory response
- replacement therapy